Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-01-07

Clinical Trial Update: Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics [Phase 3]

View source ↗

Summary

Phase 3 study evaluating benralizumab on allergen-induced inflammation in mild, atopic asthma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Benralizumab (benralizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2021-01-07